Therapy Directory

Ibrutinib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ibrutinib as a study intervention. Browse Ibrutinib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

271

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Ibrutinib, Obinutuzumab; Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Multiple Myeloma
Interventions: Ibrutinib, Carfilzomib, Dexamethasone; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Venetoclax; Drug
Lead sponsor: Steven E. Coutre; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 2
States / cities: Duarte, California • Stanford, California

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: CC-122, Ibrutinib, Obinutuzumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more

Conditions: Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Interventions: 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine; Biological
Lead sponsor: Aptevo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 8
States / cities: Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Paclitaxel, Gemcitabine; Drug
Lead sponsor: Margaret Tempero; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Portland, Oregon

Conditions: Waldenström's Macroglobulinemia
Interventions: Ibrutinib, Placebo, Rituximab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more

Conditions: High Risk Smoldering Multiple Myeloma
Interventions: Ibrutinib; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: BI 836826, Ibrutinib; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Duarte, California • Boston, Massachusetts • Portland, Oregon

Conditions: Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Chlorambucil; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: La Jolla, California • Fort Myers, Florida • West Palm Beach, Florida + 5 more

Conditions: Carcinoid Tumors, Pancreatic NET
Interventions: Ibrutinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

About this Ibrutinib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ibrutinib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ibrutinib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ibrutinib clinical trials

Filter and sort this therapy

Live official records

Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 1b Safety and Efficacy Study of TRU-016

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

About this Ibrutinib clinical trials directory page